ADMA Biologics (ADMA) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed ADMA Biologics (ADMA) over the past year, gaining 221.4% versus a loss of 29.7%. Over five years, ADMA leads with a +841.8% price change compared with +145.3% for ORKA. Oruka Therapeutics is the larger company by market cap ($5.44 billion vs $2.32 billion), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | ORKA |
|---|---|---|
| Share price | $10.36 | $82.11 |
| Market cap | $2.32B | $5.44B |
| 1-day change | +0.29% | +6.25% |
| YTD return | -43.20% | +170.90% |
| 1-year return | -29.72% | +221.37% |
| 5-year return | +841.82% | +145.25% |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | — |
| EPS (TTM) | $0.70 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | — |
| Revenue growth (YoY) | +19.63% | — |
| Net income (latest FY) | $146.93M | $-105.43M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | — |
| Net margin | 28.80% | — |
| 52-week high | $20.46 | $115.52 |
| 52-week low | $7.21 | $24.46 |
| Distance from 52-week high | -49.36% | -28.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +64.09% | +88.77% |
| Average volume | 2.66M | 902.84K |
| Shares outstanding | 223.98M | 66.21M |
| Employees | 640 | 68 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 2.3 times larger than ADMA Biologics by market value ($5.44B vs $2.32B).
- ORKA has outperformed ADMA by 251.1 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Healthcare · Biotechnology · 640 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Healthcare · Biotechnology · 68 employees
ADMA vs ORKA FAQ
Which is bigger, ADMA Biologics or Oruka Therapeutics?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.44B compared with $2.32B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or ORKA?
ORKA returned +221.37% over the past 12 months, compared with -29.72% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.